Stay updated with breaking news from Sell Target. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Collegium's new products from the BDSI acquisition have already helped it report record revenue. Read more to see my strategy to accumulate COLL stock.
Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, ESPR said it has hit 100% MACE-4 accumulation.
PacBio’s HiFi and SMRT sequencing technology continues to fuel growth. PACB believes itself to be on track to hit its full-year revenue guidance of ~$160-$170M. See why I rate PACB as a buy.